Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company whose news flow is driven by developments in its allogeneic CAR-T cell therapy programs and related corporate updates. The company focuses on vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
News about Caribou frequently covers clinical trial milestones, including data readouts from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. Company press releases have highlighted efficacy and durability data in defined patient cohorts, safety profiles that support outpatient administration for vispa-cel, and dose selection and expansion plans for CB-011 in heavily pretreated multiple myeloma populations.
Investors and followers of CRBU can also expect updates on regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug status, as well as communications about planned pivotal trial designs. In addition, Caribou issues quarterly financial results and business updates via press releases and Form 8-K filings, which provide context on its operating runway, research and development spending, and strategic pipeline prioritization.
Another recurring category of news involves conference participation and webcasts, where Caribou’s management and clinical investigators present data at major hematology and oncology meetings and biopharma investor conferences. These events often coincide with new clinical data disclosures or discussions of next steps in trial development.
This news page aggregates such announcements so readers can follow Caribou’s progress in CRISPR-based genome editing, allogeneic CAR-T development, and its lead programs in lymphoma and multiple myeloma. For those tracking CRBU, regular review of this feed helps monitor key clinical, regulatory, and corporate milestones.
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
Caribou Biosciences, Inc. (Nasdaq: CRBU) reported its first quarter 2024 financial results and pipeline progress, highlighting advancements in clinical-stage programs for hematologic malignancies and autoimmune diseases. With $345.9 million in cash, cash equivalents, and marketable securities, the company expects to fund operations into Q1 2026. Notable milestones include presenting clinical data at the 2024 ASCO Annual Meeting, initiating the GALLOP Phase 1 trial, and providing updates on ongoing trials. Despite a slight decrease in licensing and collaboration revenue, increased R&D and G&A expenses led to a net loss of $41.2 million for Q1 2024.
Caribou Biosciences, Inc. (Nasdaq: CRBU) will participate in upcoming investor conferences, including the 2024 RBC Capital Markets Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The company will present at these events, offering webcasts for more information.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.